Board of directors

From 2007 to end 2010, Martin served as President and Chief Executive Officer of Biovitrum AB and Sobi AB. From 1999 to 2007 he held various Executive Vice President positions at AstraZeneca Plc. and was a member of the Senior Executive Committee. He has held and holds various chairman and board member positions in biotech and biopharma companies. Currently he serves as Chairman of Zealand Pharma AS and is a board member of Basilea Pharmaceutica Ltd. Martin is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from Uppsala University.

Anders is Chief Investment Officer of the life science investment company Radforsk, which is focused on immunotherapies and precision medicines. He is an experienced investment and business development professional in the life science industry. His roles and responsibilities cover management positions, strategy and business development, research collaborations, licensing deals, M&A and IPOs. Anders also holds several chairman and non-executive director positions with Norwegian biotech companies. He has a MBE degree.

Einar works as a strategic advisor with Cipriano AS. He was previously a partner of Wikborg Rein & Co and a partner of Arctic Securities ASA. He has held and holds various positions as chairman and board member of both Norwegian and international listed and unlisted companies. He has a Master of Law degree (cand.jur.) from the University of Oslo.

Jan is the sole owner of Datum AS and Datum Invest AS, and he is a major shareholder of Nykode. He has extensive investment experience from private and listed companies in Norway and abroad. Jan has a business degree (siviløkonom) from the BI Norwegian Business School.

Lars is a business and management consultant with a background in pharmaceutical marketing and business. His past roles include managerial and marketing positions with Merck & Co. Inc., MSD Norway, and Bringwell AB. He now serves as chairman of the board of the Norwegian Life Science Cluster, Palion Medical AS, SonoClear AS and Nisonic AS. Lars has a BSc degree in nursing and a graduate diploma in business and administration (Bedriftsøkonomisk Kandidat) from the BI Norwegian Business School.

Bernd serves as chairman or board member of several public and private biotech companies in the U.S., Canada and Europe, including BioInvent, Oxford BioTherapeutics, Aprea, CryptoMedix and Oncolytics. In addition, he serves on the advisory board of Pureos Ventures (BB Biotech/Bank Bellevue, Zurich) and is senior advisor to Hadean Ventures (Oslo and Stockholm). Previous senior executive positions in big pharma and biotech include CEO of GPC Biotech; VP Oncology and (in parallel) VP of Corporate Alliances at Bristol-Myers Squibb; and CEO and SVP & CSO of Genome Therapeutics Corporation. Moreover, he held senior faculty positions at Harvard Medical School, Massachusetts General Hospital, and Princeton University. Bernd is also a medical doctor and holds a Ph.D. in neurobiology.

Birgitte currently serves as Senior Vice President, Head of Clinical Development and Medical Affairs of Ascendis Pharma A/S (Nasdaq-listed) and as a non-executive director of Soleno Therapeutics Inc. (Nasdaq-listed). Before that, she served as the President R&D at AVROBIO Inc. (Nasdaq-listed), a clinical stage gene therapy company, and as head of R&D in Rare Diseases for GlaxoSmithKline. Previous senior executive positions in big pharma and biotech include CMO and SVP of Development at Swedish Orphan Biovitrum AB. Her career also includes various positions at Amgen Inc., including Executive Development Director of Bone, Neuroscience & Inflammation. Birgitte received her M.D. and Ph.D. degrees from Copenhagen University.

Christian is a partner at Andenæsgruppen. His prior professional experience and past roles include M&A, business development, and equity research with Norsk Hydro, Aker RGI, Morgan Stanley and Merrill Lynch. He is a CFA charterholder, has an MBA from IMD and holds a business degree (siviløkonom) from the Norwegian School of Economics and Business Administration. In addition, Christian completed the first two years of law school at the University of Oslo.

Trygve is an Investment Director with Rasmussengruppen, a major shareholder of Nykode. Previously, he worked as an equity analyst with DNB Markets and as product manager with ABB. Trygve has held several board positions with Norwegian companies and has a Ph.D. in Engineering Cybernetics from the Norwegian University of Science and Technology (NTNU).